Mycophenolate
- TRADE NAMES: CellCept (Roche); Myfortic (Novartis)
- INDICATIONS: Prophylaxis of organ rejection
- SYNONYM: mycophenolate mofetil, mycophenolate sodium, mycophenolic acid
- CLASS: Immunosuppressant
- HALF-LIFE: 18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antacids, Azathioprine, Basiliximab, Belatacept, Cholestyramine, Ciprofloxacin, Corticosteroids, Cyclophosphamide, Cyclosporine, Daclizumab, Gemifloxacin, Hemophilus B Vaccine, Levofloxacin, Mercaptopurine, Metronidazole, Moxifloxacin, Norfloxacin, Ofloxacin, Pantoprazole, Rifapentine, Sevelamer, Tacrolimus, Vaccines
PREGNANCY CATEGORY: D
EMBRYOFETAL TOXICITY, MALIGNANCIES AND SERIOUS INFECTIONS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of mycophenolate in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
